Wednesday, 28 February 2024


Glucotrack appoints new chairman with MedTech experience By

Former Indiana Congressman Charged with Insider Trading

© Reuters.

RUTHERFORD, NJ – Glucotrack, Inc. (NASDAQ:GCTK), a company specializing in diabetes management technology, has announced the appointment of Luis Malavé as the new Chairman of its Board of Directors, effective immediately. The announcement was made today, signaling a strategic move for the medical device firm as it continues to develop innovative solutions for diabetes care.

With over three decades of leadership in the MedTech industry, Malavé’s experience spans across various stages of company growth, from startups to large-cap public entities. His expertise is particularly strong in diabetes management, having held significant roles in product development, operations, marketing, strategic partnerships, and regulatory strategy. Notably, Malavé currently presides as President of EOFLOW CO. Ltd., which has introduced a wearable disposable insulin pump to the market.

Previously, Malavé served as President and CEO of Palyon Medical and held leadership positions at Insulet (NASDAQ:) Corp. and MiniMed, contributing to their growth and innovation before their acquisition by Medtronic (NYSE:). His educational background includes a Bachelor’s degree in Mathematics and Computer Science, a Master’s in Software Engineering, and an MBA.

Andrew Sycoff, a member of Glucotrack’s Board, expressed confidence in Malavé’s ability to lead the board during a critical phase for the company, citing his commitment to the company’s mission and values. Malavé, who has been on Glucotrack’s Board since 2021, shared his enthusiasm for the role, emphasizing the opportunity to address unmet needs in the diabetes market with Glucotrack’s technology.

Paul V. Goode, PhD, President & CEO of Glucotrack, highlighted Malavé’s understanding of the diabetes sector and his advocacy for the company’s vision, noting the benefits his experience will bring as Glucotrack advances the development of its implantable Continuous Blood Glucose Monitor (CBGM) for individuals with diabetes.

Glucotrack is actively working on a long-term implantable glucose monitoring system, aiming to expand patient choice and improve quality of life for those living with diabetes.

This appointment is based on a press release statement.

InvestingPro Insights

Amidst the strategic leadership changes at Glucotrack, Inc. (NASDAQ:GCTK), investors and industry watchers are closely monitoring the company’s financial health and market performance. Glucotrack’s appointment of Luis Malavé as Chairman of…

Click Here to Read the Full Original Article at All News…